Skip to main content

Table 1 Study population characteristics according to obesity status (ANRS CO22 Hepather cohort, N = 6348)

From: Cannabis use as a factor of lower corpulence in hepatitis C-infected patients: results from the ANRS CO22 Hepather cohort

Variable (% of missing values)

 

Central obesitya

  

Underweight or normal weight

Overweight

Obesity

 

Study population (N = 6348)

No (N = 2832)

Yes (N = 3516)

P-valueb

BMI < 25 kg/m2 (N = 3443)

25 ≤ BMI < 30 kg/m2 (N = 2038)

BMI ≥ 30 kg/m2 (N = 867)

P-value

N (%)

N (%)

N (%)

 

N (%)

N (%)

N (%)

 

Sex

 Male

3418 (53.8)

1744 (61.6)

1674 (47.6)

< 10−3

1708 (49.6)

1288 (63.2)

422 (48.7)

< 10−3

 Female

2930 (46.2)

1088 (38.4)

1842 (52.4)

 

1735 (50.4)

750 (36.8)

445 (51.3)

 

Age at baseline (years)

 Median [IQR]

56 [50–64]

53 [48–61]

58 [51–66]

< 10−3

55 [49–63]

57 [50–65]

57 [50–65]

< 10−3

Place of birth (0.1)

 France

4673 (73.6)

2188 (77.3)

2485 (70.7)

< 10−3

2671 (77.6)

1460 (71.7)

542 (62.6)

< 10−3

 Europe + North America + Latin America + Australiac

486 (7.7)

221 (7.8)

265 (7.5)

 

246 (7.1)

160 (7.9)

80 (9.2)

 

 North Africa + Middle East

576 (9.1)

212 (7.5)

364 (10.4)

 

259 (7.5)

207 (10.2)

110 (12.7)

 

 Sub-Saharan Africa + the Caribbeand

412 (6.5)

117 (4.1)

295 (8.4)

 

153 (4.4)

157 (7.7)

102 (11.8)

 

 Asia

198 (3.1)

93 (3.3)

105 (3.0)

 

113 (3.3)

53 (2.6)

32 (3.7)

 

Coffee consumption (0.7)

 0 cups/day

1795 (28.5)

733 (26.1)

1062 (30.4)

< 10−3

915 (26.8)

594 (29.3)

286 (33.3)

0.002

 1–2 cups/day

2531 (40.2)

1087 (38.7)

1444 (41.4)

 

1 391 (40.7)

806 (39.8)

334 (38.9)

 

 ≥ 3 cups/day

1977 (31.4)

991 (35.3)

986 (28.2)

 

1112 (32.5)

627 (30.9)

238 (27.7)

 

Cannabis use

 Never

4271 (67.3)

1632 (57.6)

2639 (75.1)

< 10−3

2131 (61.9)

1446 (71.0)

694 (80.0)

< 10−3

 Former

1292 (20.4)

680 (24.0)

612 (17.4)

 

753 (21.9)

410 (20.1)

129 (14.9)

 

 Current

785 (12.4)

520 (18.4)

265 (7.5)

 

559 (16.2)

182 (8.9)

44 (5.1)

 

Tobacco smoking

 Never

2390 (37.7)

861 (30.4)

1529 (43.5)

< 10−3

1200 (34.9)

795 (39.0)

395 (45.6)

< 10−3

 Former

1747 (27.5)

730 (25.8)

1017 (28.9)

 

866 (25.2)

616 (30.2)

265 (30.6)

 

 Current

2210 (34.8)

1241 (43.8)

969 (27.6)

 

1377 (40.0)

627 (30.8)

206 (23.8)

 

Alcohol consumption (0.4)

 Abstinent without past unhealthy use

2723 (43.1)

1084 (38.4)

1639 (46.8)

< 10−3

1401 (40.8)

888 (43.8)

434 (50.4)

< 10−3

 Moderate use

2521 (39.9)

1241 (44.0)

1280 (36.6)

 

1448 (42.2)

786 (38.7)

287 (33.3)

 

 Unhealthy use (past or current)

1077 (17.0)

496 (17.6)

581 (16.6)

 

582 (17.0)

355 (17.5)

140 (16.3)

 

Living in poverty (2.6)

 No

4303 (69.6)

1974 (71.6)

2329 (67.9)

0.002

2411 (72.0)

1372 (68.8)

520 (61.7)

< 10−3

 Yes

1883 (30.4)

782 (28.4)

1101 (32.1)

 

939 (28.0)

621 (31.2)

323 (38.3)

 

Education level (1.1)

 < upper secondary school certificate

3396 (54.1)

1359 (48.5)

2037 (58.6)

< 10−3

1710 (50.3)

1148 (56.7)

538 (63.0)

< 10−3

 ≥ upper secondary school certificate

2883 (45.9)

1443 (51.5)

1440 (41.4)

 

1692 (49.7)

875 (43.3)

316 (37.0)

 

Employed (0.4)

 No

3518 (55.6)

1308 (46.4)

2210 (63.1)

< 10−3

1797 (52.4)

1146 (56.4)

575 (66.7)

< 10−3

 Yes

2807 (44.4)

1513 (53.6)

1294 (36.9)

 

1633 (47.6)

887 (43.6)

287 (33.3)

 

Advanced liver fibrosise (6.6)

 No

4391 (74.0)

2049 (78.4)

2342 (70.6)

< 10−3

2429 (75.9)

1387 (72.3)

575 (70.8)

0.001

 Yes

1541 (26.0)

566 (21.6)

975 (29.4)

 

772 (24.1)

532 (27.7)

237 (29.2)

 

Time since HCV diagnosis (years) (2.0)

 Median [IQR]

14.0 [6.7–19.8]

14.4 [6.8–19.9]

13.7 [6.7–19.7]

0.126

14.4 [7.2–20.0]

13.8 [6.8–19.6]

12.7 [6.0–19.1]

0.002

HCV treatment history

 Never

3289 (51.8)

1586 (56.0)

1703 (48.4)

< 10−3

1938 (56.3)

960 (47.1)

391 (45.1)

< 10−3

 Interferon-based

2278 (35.9)

947 (33.4)

1331 (37.9)

 

1146 (33.3)

794 (39.0)

338 (39.0)

 

 1st or 2nd generation DAA

616 (9.7)

226 (8.0)

390 (11.1)

 

267 (7.8)

231 (11.3)

118 (13.6)

 

 Other

165 (2.6)

73 (2.6)

92 (2.6)

 

92 (2.7)

53 (2.6)

20 (2.3)

 
  1. BMI body mass index, DAA direct-acting antiviral, HCV hepatitis C virus, IQR interquartile range
  2. aCentral obesity was defined as having a waist circumference ≥ 94 cm for men (except for men born in Asia, Central or South America, for whom the cut-off was set at 90 cm) and ≥ 80 cm for women (World Health Organization 2019)
  3. bThe chi-squared and Student’s t tests were used in these comparisons for categorical and continuous variables, respectively
  4. c23 participants were born in Latin America, 15 in the USA, and 2 in Australia
  5. d10 participants were born in the Caribbean
  6. eAdvanced liver fibrosis was defined as an FIB-4 score >3.25 (Sterling et al. 2006)
Back to article page

Journal of Cannabis Research

ISSN: 2522-5782